Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05838729 · ClinicalTrials.gov registry record · Phase 1
Study of RiMO-301 and Radiotherapy With PD-1 Inhibitor for the Treatment of Head-Neck Cancer
A Phase 1 study of Head Neck Cancer and Intratumoral Injection, sponsored by Coordination Pharmaceuticals.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
- 1
- Study location
NCT05838729 is a Phase 1 study of Head Neck Cancer and Intratumoral Injection that is actively recruiting participants, run by Coordination Pharmaceuticals. The registered enrollment target is 16 participants, below the 39-participant average among 6 other Head Neck Cancer trials with a reported enrollment target (59% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05838729, a Phase 1 study of Head Neck Cancer and Intratumoral Injection, is actively recruiting participants, sponsored by Coordination Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a prospective, open-label, single arm, non-randomized study of RiMO-301 with hypofractionated radiation and a PD-1 Inhibitor in patients with unresectable, recurrent or metastatic head-neck cancer.
Conditions Studied
Interventions
- DRUG RiMO-301
Study Locations (1)
Illinois
- University of Illinois at Chicago - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2023-04-03 |
| Est. Completion | 2026-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05838729
The ClinicalTrials.gov registry entry for NCT05838729 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 39-participant average among 6 other Head Neck Cancer trials with a reported enrollment target (59% lower). The listed sponsor is Coordination Pharmaceuticals, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Head Neck Cancer appearing as the primary indexed condition, and to 1 intervention - of which RiMO-301 is the first listed.
NCT05838729 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT05838729 about?
NCT05838729 is a clinical study titled "Study of RiMO-301 and Radiotherapy With PD-1 Inhibitor for the Treatment of Head-Neck Cancer". This is a prospective, open-label, single arm, non-randomized study of RiMO-301 with hypofractionated radiation and a PD-1 Inhibitor in patients with unresectable, recurrent or metastatic head-neck cancer.
What is the current status of trial NCT05838729?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2023-04-03. Estimated completion is 2026-12.
What conditions does trial NCT05838729 study?
This clinical trial studies the following conditions: Head Neck Cancer, Intratumoral Injection.
What interventions are being tested in trial NCT05838729?
The interventions under investigation include: RiMO-301 (DRUG).
Who is sponsoring clinical trial NCT05838729?
This trial is sponsored by Coordination Pharmaceuticals, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05838729 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Head Neck Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Intratumoral Delivery of Viral Replicon (saRNA) Particles Expressing IL-12 in Head and Neck Cancer
RECRUITING · Phase 1
-
A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants with Advanced Unresectable or Metastatic Solid Tumors
ACTIVE NOT RECRUITING · Phase 1
-
Weekly Nanoparticle Albumin-Bound Paclitaxel (Abraxane) + Weekly Cetuximab + Radiation Therapy (IMRT, Intensity-Modulated Radiation Therapy) in Patients With Stage III-IVB Head and Neck Squamous Cell Carcinoma (HNSCC)
COMPLETED · Phase 1
-
RAD001 (Everolimus) + Docetaxel + Cisplatin as Induction Chemotherapy in Patients With Local-Regional Advanced Head and Neck Cancer
COMPLETED · Phase 1
-
First Line Weekly Chemo/Immunotherapy for Metastatic Head/Neck Squamous Cell Carcinoma Patients
RECRUITING · Phase 2
-
Stereotactic MRI-guided Focused Ultrasound Mesencephalotomy
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.